7,978 Shares in Incyte Co. (NASDAQ:INCY) Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. purchased a new stake in Incyte Co. (NASDAQ:INCY - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 7,978 shares of the biopharmaceutical company's stock, valued at approximately $551,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Incyte during the third quarter worth approximately $292,000. PNC Financial Services Group Inc. grew its position in Incyte by 42.1% during the third quarter. PNC Financial Services Group Inc. now owns 30,649 shares of the biopharmaceutical company's stock valued at $2,026,000 after acquiring an additional 9,083 shares during the period. Commerce Bank purchased a new position in shares of Incyte in the 3rd quarter worth about $610,000. Advisors Asset Management Inc. grew its holdings in shares of Incyte by 2.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 15,244 shares of the biopharmaceutical company's stock worth $1,008,000 after purchasing an additional 386 shares during the period. Finally, Massachusetts Financial Services Co. MA purchased a new position in Incyte in the third quarter valued at approximately $4,739,000. Hedge funds and other institutional investors own 96.97% of the company's stock.

Insider Buying and Selling at Incyte

In other Incyte news, EVP Sheila A. Denton sold 599 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total value of $41,924.01. Following the transaction, the executive vice president now owns 25,848 shares of the company's stock, valued at approximately $1,809,101.52. This represents a 2.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Steven H. Stein sold 12,352 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total value of $897,866.88. Following the sale, the executive vice president now directly owns 66,967 shares of the company's stock, valued at approximately $4,867,831.23. This represents a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 46,827 shares of company stock valued at $3,322,618 in the last quarter. Corporate insiders own 17.60% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Citigroup decreased their price target on shares of Incyte from $97.00 to $88.00 and set a "buy" rating for the company in a research report on Tuesday, February 11th. Truist Financial lowered their target price on Incyte from $74.00 to $72.00 and set a "hold" rating for the company in a research note on Tuesday, March 18th. JMP Securities reissued a "market perform" rating on shares of Incyte in a research report on Tuesday, February 11th. StockNews.com downgraded shares of Incyte from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 12th. Finally, UBS Group started coverage on shares of Incyte in a research report on Tuesday, December 17th. They set a "neutral" rating and a $77.00 target price on the stock. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $74.88.

Incyte Stock Performance

INCY traded down $0.70 during trading on Tuesday, reaching $62.08. 2,603,519 shares of the company were exchanged, compared to its average volume of 2,267,810. Incyte Co. has a 52 week low of $50.35 and a 52 week high of $83.95. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average of $70.42 and a 200 day moving average of $70.17. The stock has a market cap of $12.01 billion, a P/E ratio of 229.93, a PEG ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY - Get Free Report) last posted its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. On average, sell-side analysts forecast that Incyte Co. will post 4.86 EPS for the current fiscal year.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.